文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症人感染H7N9禽流感早期集束化治疗方案的设计与应用

[Design and application of bundle treatment plan in the early stage for severe human infection by avian influenza H7N9].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2018-01-01
一句话结论重症H7N9禽流感早期集束化治疗组死亡2例,低于常规治疗组5例(P=0.041),作者认为可改善预后、降低病死率。

该研究纳入2016年12月29日至2017年6月7日贵州省15例重症人感染H7N9禽流感患者,2017年3月6日至6月7日收治者9例为前瞻性观察期(集束化治疗组),2016年12月29日至2017年3月5日收治者6例为历史对照期(常规治疗组)。集束化治疗组在隔离、抗病毒、对症、中医药等常规治疗基础上加用呼吸支持、限制性液体管理、免疫治疗、抑制炎症、抗生素治疗、营养支持、医院获得性肺炎(HAP)预防、个体化镇静、对急性肾损伤(AKI)及重度急性呼吸窘迫综合征(ARDS)患者行连续血液净化(CBP)及重症监护,并成立集束化治疗团队。两组性别、年龄、发病至确诊时间、APACHE II评分、入ICU时PaO2/FiO2、ICU住院时间、总住院时间无显著差异,但集束化治疗组死亡2例、常规治疗组死亡5例(χ2=3.225,P=0.041)。Spearman相关分析示病死率与是否接受集束化治疗显著相关(r=-0.875,P=0.018);未接受集束化治疗预测死亡的AUC为0.938(95%CI 0.795-1.000),敏感度88.88%,特异度98.62%。

要点

  • 重症H7N9禽流感患者早期集束化治疗组死亡2例 vs 常规治疗组5例(χ2=3.225,P=0.041)。
  • 集束化治疗组与常规治疗组性别、年龄、发病至确诊时间、APACHE II评分、入ICU时PaO2/FiO2、ICU住院时间、总住院时间均无显著差异。
  • Spearman相关分析示重症H7N9禽流感病死率与是否接受集束化治疗显著相关(r=-0.875,P=0.018)。
  • 未接受集束化治疗预测重症H7N9禽流感死亡的AUC为0.938(95%CI 0.795-1.000),敏感度88.88%,特异度98.62%。
  • 集束化方案含隔离、抗病毒、呼吸支持、限制性液体管理、免疫治疗、抑制炎症、抗生素治疗、营养支持、HAP预防、个体化镇静,以及对AKI和重度ARDS患者行CBP。

适用人群与场景

  • 2016年12月29日至2017年6月7日贵州省收治的15例重症人感染H7N9禽流感患者。
  • 2017年3月6日至6月7日收治的9例为前瞻性观察期(集束化治疗组)。
  • 2016年12月29日至2017年3月5日收治的6例为历史对照期(常规治疗组)。

处置流程与药物剂量

  • 常规治疗组给予隔离、抗病毒、对症治疗及中医药等常规治疗。
  • 集束化治疗组在常规治疗基础上加用隔离、抗病毒、呼吸支持、限制性液体管理、免疫治疗、抑制炎症、抗生素治疗、营养支持、预防医院获得性肺炎(HAP)、个体化镇静。
  • 集束化治疗组中对急性肾损伤(AKI)及重度急性呼吸窘迫综合征(ARDS)患者行连续血液净化(CBP)。
  • 成立集束化治疗团队以保证各项措施顺利实施。

研究设计与关键结果

  • 研究类型为前瞻性观察期与历史对照期比较,共纳入15例重症人感染H7N9禽流感患者,集束化治疗组9例、常规治疗组6例。
  • 两组性别、年龄、发病至确诊时间、APACHE II评分、入ICU时PaO2/FiO2、ICU住院时间、总住院时间无显著差异。
  • 集束化治疗组死亡2例 vs 常规治疗组死亡5例(χ2=3.225,P=0.041)。
  • Spearman相关分析示重症H7N9禽流感患者病死率与是否接受集束化治疗显著相关(r=-0.875,P=0.018)。
  • ROC曲线分析示未接受集束化治疗预测重症人感染H7N9禽流感患者死亡的AUC为0.938(95%CI 0.795-1.000),敏感度88.88%,特异度98.62%。

证据类型、等级与局限

  • 证据类型为前瞻性观察期与历史对照期比较的临床研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为早期集束化治疗对重症人感染H7N9禽流感效果显著,可改善预后、降低病死率,值得临床应用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To design bundle treatment plan in the early stage for severe human infection by avian influenza H7N9, and explore its clinical efficacy and application value.

METHODS: Fifteen patients with severe human infection by avian influenza H7N9 in Guizhou Province from December 29th, 2016 to June 7th, 2017 were enrolled. Patients admitted from March 6th, 2017 to June 7th, 2017 served as a prospective observation period (bundle treatment group), and those from December 29th, 2016 to March 5th, 2017 were selected as a historical control period (conventional treatment group). Conventional treatment group was given conventional treatment such as isolation, anti-virus, symptomatic treatment, and traditional Chinese medicine and so on. Bundle treatment group was given bundle treatment on the basis of conventional treatment, including isolation, anti-virus, respiratory support, restrictive fluid management, immunotherapy, inhibition of inflammation, antibiotic therapy, nutritional support, prevention of hospital acquired infection (HAP), individual sedation, continuous blood purification (CBP) for acute kidney injury (AKI) and severe acute respiratory distress syndrome (ARDS) patients, and intensive care. A cluster of bundle treatment team was set up to ensure that all measures carried out smoothly. The gender, age, onset to diagnosis time, acute physiology and chronic health evaluation II (APACHE II) score, oxygenation index (PaO2/FiO2) at admission, the length of intensive care unit (ICU) stay, total hospitalization time and prognosis of the two groups were observed. Correlation analysis between bundle therapy and prognosis was analyzed by Spearman correlation analysis. Receiver operating characteristic (ROC) curve was drawn, and the clinical value of bundle treatment was analyzed.

RESULTS: There was no significant difference in gender, age, onset to diagnosis time, APACHE II score, PaO2/FiO2, the length of ICU stay, or total hospitalization time between bundle treatment group (n = 9) and conventional treatment group (n = 6), but the death patients in the bundle treatment group was significantly fewer than those in conventional treatment group (cases: 2 vs. 5, χ2 = 3.225, P = 0.041). Correlation analysis showed that there was a significant correlation between the mortality and whether received bundle treatment or not in patients who infected by avian influenza H7N9 (r = -0.875, P = 0.018). ROC curve analysis showed that the area under the ROC curve (AUC) of non-bundle treatment for predicting the death in patients with severe human infection by avian influenza H7N9 was 0.938, 95% confidence interval (95%CI) was 0.795-1.000, the sensitivity was 88.88%, and the specificity was 98.62%.

CONCLUSIONS: Early bundle therapy has a significant effect on severe human infection by avian influenza H7N9, which can improve the prognosis and reduce the mortality of patients. It is worthy for clinical application.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Wang L, Fang X, Yang Y, et al. [Design and application of bundle treatment plan in the early stage for severe human infection by avian influenza H7N9]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018. PMID: 29308753. doi:10.3760/cma.j.issn.2095-4352.2018.01.005

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。